Generation of T cell effectors using tumor cell-loaded dendritic cells for adoptive T cell therapy
Language English Country United States Media print-electronic
Document type Journal Article
PubMed
27812850
DOI
10.1007/s12032-016-0855-4
PII: 10.1007/s12032-016-0855-4
Knihovny.cz E-resources
- Keywords
- Adoptive T cell therapy, Cancer immunotherapy, Prostate cancer, Tumor-specific T cell expansion,
- MeSH
- Lymphocyte Activation MeSH
- Antigens, Neoplasm immunology MeSH
- Bioreactors MeSH
- Dendritic Cells immunology MeSH
- Epitopes, T-Lymphocyte immunology MeSH
- Immunotherapy, Adoptive methods MeSH
- Interferon-gamma biosynthesis immunology MeSH
- Humans MeSH
- Cell Line, Tumor MeSH
- Prostatic Neoplasms immunology MeSH
- Ovarian Neoplasms immunology MeSH
- T-Lymphocytes, Regulatory immunology MeSH
- Case-Control Studies MeSH
- T-Lymphocyte Subsets immunology MeSH
- T-Lymphocytes immunology MeSH
- Check Tag
- Humans MeSH
- Male MeSH
- Female MeSH
- Publication type
- Journal Article MeSH
- Names of Substances
- Antigens, Neoplasm MeSH
- Epitopes, T-Lymphocyte MeSH
- Interferon-gamma MeSH
Adoptive T cell transfer has been shown to be an effective method used to boost tumor-specific immune responses in several types of malignancies. In this study, we set out to optimize the ACT protocol for the experimental treatment of prostate cancer. The protocol includes a pre-stimulation step whereby T cells were primed with autologous dendritic cells loaded with the high hydrostatic pressure-treated prostate cancer cell line, LNCaP. Primed T cells were further expanded in vitro with anti-CD3/CD28 Dynabeads in the WAVE bioreactor 2/10 system and tested for cytotoxicity. Our data indicates that the combination of pre-stimulation and expansion steps resulted in the induction and enrichment of tumor-responsive CD4+ and CD8+ T cells at clinically relevant numbers. The majority of both CD4+ and CD8+ IFN-γ producing cells were CD62L, CCR7 and CD57 negative but CD28 and CD27 positive, indicating an early antigen experienced phenotype in non-terminal differentiation phase. Expanded T cells showed significantly greater cytotoxicity against LNCaP cells compared to the control SKOV-3, an ovarian cancer line. In summary, our results suggest that the ACT approach together with LNCaP-loaded dendritic cells provides a viable way to generate prostate cancer reactive T cell effectors that are capable of mounting efficient and targeted antitumor responses and can be thus considered for further testing in a clinical setting.
Department of Pediatric and Adult Rheumatology Faculty Hospital Motol Prague Czech Republic
Laboratory of Immunobiology Institute of Molecular Genetics of the AS CR Prague Czech Republic
See more in PubMed
J Exp Med. 2005 Oct 3;202(7):907-12 PubMed
J Transl Med. 2012 Aug 21;10:169 PubMed
J Transl Med. 2012 Apr 04;10:69 PubMed
J Immunol. 2006 Nov 1;177(9):6527-39 PubMed
Clin Cancer Res. 2012 Dec 15;18(24):6758-70 PubMed
Curr Opin Immunol. 2014 Apr;27:1-7 PubMed
Curr Opin Investig Drugs. 2007 Dec;8(12):1002-8 PubMed
J Immunother. 2005 May-Jun;28(3):258-67 PubMed
Clin Cancer Res. 2010 May 1;16(9):2646-55 PubMed
Oncoimmunology. 2016 Jul 01;5(8):e1202391 PubMed
J Immunol Methods. 2010 Apr 15;355(1-2):52-60 PubMed
Clin Cancer Res. 2011 Jul 1;17(13):4550-7 PubMed
J Immunol Methods. 1987 Aug 24;102(1):127-41 PubMed
Cancer Res. 2010 Nov 1;70(21):8378-87 PubMed
J Immunol Methods. 2003 Apr 1;275(1-2):251-5 PubMed
Int J Oncol. 2016 Mar;48(3):953-64 PubMed
J Biomed Biotechnol. 2010;2010:956304 PubMed
Cancer Res. 2011 May 15;71(10 ):3540-51 PubMed
J Immunol. 2001 Aug 1;167(3):1712-9 PubMed
Int J Cancer. 2014 Sep 1;135(5):1165-77 PubMed
Blood. 2005 Jan 1;105(1):241-50 PubMed
Nat Rev Cancer. 2012 Mar 22;12(4):252-64 PubMed
Prostate. 2007 Mar 1;67(4):389-95 PubMed
J Immunother. 2003 Jul-Aug;26(4):332-42 PubMed
J Immunol. 2005 Mar 1;174(5):2591-601 PubMed
J Urol. 1997 Sep;158(3 Pt 1):740-5 PubMed
Annu Rev Immunol. 2014;32:189-225 PubMed
J Immunol. 1984 Oct;133(4):1710-5 PubMed
Blood. 2007 Aug 15;110(4):1123-31 PubMed
CA Cancer J Clin. 2015 Jan-Feb;65(1):5-29 PubMed
Science. 2002 Oct 25;298(5594):850-4 PubMed
Int J Cancer. 2010 Aug 15;127(4):748-58 PubMed
Eur J Cancer. 2016 Jan;52:50-66 PubMed
Oncoimmunology. 2015 Jan 7;3(12):e968434 PubMed
Proc Natl Acad Sci U S A. 2004 Oct 5;101 Suppl 2:14639-45 PubMed
J Transl Med. 2010 Oct 26;8:104 PubMed
Science. 2015 Apr 3;348(6230):69-74 PubMed
Int J Cancer. 2010 Apr 1;126(7):1582-95 PubMed
Immunol Lett. 2014 Jul;160(1):39-49 PubMed
Hum Vaccin Immunother. 2015;11(12):2790-5 PubMed
Nat Immunol. 2000 Nov;1(5):433-40 PubMed
Clin Cancer Res. 2016 Aug 1;22(15):3734-45 PubMed
Cancer Immunol Immunother. 2003 Jul;52(7):445-54 PubMed
Clin Cancer Res. 2007 Mar 15;13(6):1883-91 PubMed
